ILMN
Illumina, Inc.
October 6, 2026 · intraday
- Rarity
- 1.37
- Peak move
- −7.62%
- Float cap
- $44.8B
Illumina provides sequencing- and array-based solutions for genetic and genomic analysis. Its integrated systems, consumables, and analysis tools are used by genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories, and consumer genomics firms. The company serves research, applied, and clinical markets, including oncology, genetic health, and reproductive health.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
8 events · 0 from SEC or newswire · 0 timed with the moveinsider_saleIllumina director Keith Meister elected to receive his Q3 2026 board and committee compensation entirely in shares, receiving 107 shares.
analyst_ratingRBC Capital analyst Dan Leonard raised the price target on Illumina to $310 from $230 and kept an Outperform rating, citing a multiple re-rating from clinical sales inflection and positive catalysts.
analyst_ratingWall Street Zen downgraded Illumina to Hold from Buy in a report released Saturday, October 3, 2026.
insider_saleIllumina disclosed insider transactions: director Scott B. Ullem bought 113 shares and directors Keith A. Meister and Ullem bought a combined 220 shares at $219.80 on September 30, 2026.
insider_saleIllumina director Keith A. Meister received 107 shares of common stock on September 30, 2026 at a reference price of $219.8037 per share as his Q3 2026 board and committee retainer, paid 100% in stock.
analyst_ratingGuggenheim analyst Subbu Nambi raised the price target on Illumina to $305 from $226 and maintained a Buy rating, after updating models for diagnostics and life-science tools companies ahead of Q3 earnings season.
peer_disclosureEpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to integrate genomic and epigenomic rare-disease analysis.
major_contractAstraZeneca said it will collaborate with Illumina to develop its next-generation sequencing platform for companion diagnostic tests across AZ's oncology portfolio.